HealthLeaders Media September 23, 2022
Robin Robinson

The massive infusion puts Verily in a good deal-making position as the health-tech arena grows.


– The infusion will support Verily’s initiatives in data platforms and research and technology that individualize healthcare.

– Analysts have compared Verily’s funding to Amazon’s acquisition of One Medical – both strategies increase their footprints in the healthcare technology market.

– Verily CEO Andy Conrad will become executive chairman of the Verily Board and current president Stephen Gillett will advance to CEO, effective January 2023.

Verily Life Sciences plans to use its newest $1 billion investment round, led by its parent company, Alphabet, to support expanding its focus on precision health, which includes initiatives in real world evidence generation, healthcare data platforms, and...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Big Food vs. Big Pharma: Companies bet on snacking just as weight loss drugs boom
Preventative Drug Lists Led to More Affordable Asthma Medication
Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular Among Voters
Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

Share This Article